Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

Abstract

The results of this study suggest a structural benefit associated with zoledronic acid therapy in patients with RA, as demonstrated by consistent results in structural end points in favor of zoledronic acid plus MTX compared with MTX alone.